A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy

Exclusion Criteria

• •1. Prior exposure to any experimental or marketed uricase (e.g., pegloticase \[Krystexxa®\], pegadricase \[SEL-037\], rasburicase \[Elitek, Fasturtec\]);
• •2. History of anaphylaxis or severe allergic reactions to medications;
• •3. History of any allergy to pegylated products
• •4. Drugs known to interact with Rapamune cannot be used during the trial;
• •5. Uncontrolled diabetes;
• •6. Glucose-6-phosphate dehydrogenase (G6PD) deficiency;
• •7. Uncontrolled hypertension;
• •8. Participants whose arrhythmia is unstable on current treatment;
• •9. History of coronary artery disease, including myocardial infarction or unstable angina, within the last 6 months;
• •10. Congestive heart failure;
• •11. History of hematological disorders within 1 year or autoimmune disorders, is immunosuppressed or immunocompromised;
• •12. Has received an inactivated vaccine in the previous 3 months or has received a live virus vaccine in the previous 6 months;
• •13. Is planning to receive any vaccination or live virus vaccination during the study;